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To determine whether tuberculosis (TB) and 
nontuberculous mycobacteria (NTM) infection patients 
could be distinguished from one another with limited 
information, we compared pulmonary TB and NTM patients 
during 2005–2006. Our ﬁ   nding that age, birthplace, and 
presence of chronic obstructive pulmonary disease could 
differentiate TB and NTM disease could assist tuberculosis 
control efforts. 
P
atients seeking treatment who have respiratory 
specimens positive for acid-fast bacilli present a public 
health dilemma. Although Mycobacterium tuberculosis 
and nontuberculous mycobacteria (NTM) cause chronic 
lung infections, only tuberculosis (TB) spreads from 
person to person by inhalation of organisms expectorated 
into the air. NTM infections are acquired directly from 
the environment, where they are often present in soil and 
various water sources. The prevalence of NTM disease is 
reported to be increasing and is likely greater than that of TB 
in the United States (1–3). Because deﬁ  nitive identiﬁ  cation 
of mycobacterial species can take several weeks, the ability 
to quickly distinguish NTM from TB on clinical grounds 
could help public health ofﬁ  cials make decisions regarding 
contact investigations and isolation. To date, little 
population-based data exist that compare characteristics of 
pulmonary TB and NTM patients because previous studies 
have been limited to single institutions (4–6).
The Study
We identiﬁ  ed patients reported to the Oregon Health 
Division with pulmonary TB during 2005–2006 who 
lived within the Portland metropolitan region (Clackamas, 
Multnomah, and Washington Counties). This region had a 
combined population of ≈1.55 million in 2005–2006 (7). 
In 2000, the predominant ethnicity in this region was white 
(75.8%), followed by Hispanic or Latino (11.4%), Asian 
(6.3%), and black (3.6%), and 11.9% of the population 
had been born outside the United States (7). From a 
statewide surveillance project, we identiﬁ  ed all tri-county 
residents with NTM respiratory isolates obtained during 
the same period and then used pulmonary NTM disease 
criteria of the American Thoracic Society/Infectious 
Diseases Society of America to deﬁ  ne cases of pulmonary 
NTM disease (3,8). For each pulmonary TB and NTM 
case-patient within the tri-county region, we collected 
demographic information. From physician records, we 
collected clinical data. We conducted this project under 
the authority of the Oregon Administrative Rules for 
special studies to control a public health problem.
We used SAS version 9.1 (SAS Institute Inc., Cary, 
NC, USA) to compare categorical variables in univariate 
fashion by the χ2 or Fisher exact tests. We calculated the 
relative proportion (RP) of TB patients with each risk factor 
compared to the proportion of NTM patients with the risk 
factor. We used the Student t test to evaluate continuous 
variables. We considered factors with a p value <0.2 for 
multivariate logistic regression and performed stepwise 
backward elimination of variables not reaching levels of 
statistical signiﬁ  cance (p<0.05). Using signiﬁ  cant variables 
from our multivariate model, we calculated the positive 
predictive value (PPV) and 95% exact binomial conﬁ  dence 
intervals (CIs) of variables, alone and in combination, 
for distinguishing TB from NTM disease. Age was 
dichotomized (<50 and >50 years) based on the age of 
NTM case-patients to simplify calculation of PPV (9).
Eighty-two pulmonary TB patients were reported; all 
but 2 had complete clinical records for review. We identiﬁ  ed 
407 patients with respiratory NTM isolates. Clinical 
records were present for 283 (69.5%) of these patients, of 
whom 127 (44.9%) met clinical criteria of the American 
Thoracic Society/Infectious Diseases Society of America 
for pulmonary NTM disease (8). Fifty-four patients lacked 
information on country of birth. In patients for whom smear 
data was available, no important difference was found in 
proportion of case-patients with smear-positive results 
(38/79 [46%] of TB case-patients vs. 28/47 [60%] of NTM 
case-patients). In comparison to NTM case-patients, TB 
patients were younger (median age 44 years, range 5–86 
years vs. 67 years, range 12–92 years; p<0.01), more likely 
to be male (RP 1.6 , 95% CI 1.2–2.2, p<0.01), and more 
likely to have been born outside the United States (RP 4.0, 
95% CI 2.5–6.3, p<0.01) (Table 1). Mycobacterium avium-
intracellulare complex was the most common etiologic 
agent of NTM disease in our cohort (114 [90%]).
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Clinically, TB patients were more likely to report 
constitutional symptoms (56 [70%] vs. 61 [48%], RP 
1.5, 95% CI 1.2–1.8, p<0.01), less likely to have chronic 
obstructive pulmonary disease (COPD) (2 [3%] vs. 29 
[23%], RP 0.1, 95% CI 0.0–0.4, p<0.01]), and less likely 
to be using immunosuppressive medications than NTM 
patients (8 [10%] vs. 34 [27%], RP 0.4, 95% CI 0.2–0.8, 
p<0.01) (Table 1). The most common immunosuppressive 
medications were systemic corticosteroids (30 patients 
[14%]). Patients with TB were more likely to have 
cavitation (18 [23%] vs. 11 [9%], RP 2.7, 95% CI 1.3–5.3, 
p<0.01) and inﬁ  ltrate reported (68 [87%] vs. 69 [54%], 
RP 1.6, 95% CI 1.3–1.9, p<0.01) on chest radiograph 
(Table 1).
Birth outside the United States (odds ratio [OR] 26.3, 
95% CI 9.9–69.6, p<0.01), constitutional symptoms (OR 
3.0, 95% CI 1.1–8.0, p = 0.03), and inﬁ  ltrate on chest 
radiograph (OR 7.8, 95% CI 2.6–23.9, p<0.01) were 
signiﬁ  cantly associated with TB in multivariate analysis. 
Age was inversely related to the likelihood of having TB 
with an OR of 0.95 (95% CI 0.93–0.98, p<0.01) for each 
year increase in age. Because of its clinical signiﬁ  cance, 
COPD (OR 0.3, 95% CI 0.1–1.7, p = 0.19) was maintained 
in the multivariate model. Four patients with missing 
covariate data were excluded (Table 1).
In our predictive model, age <50 years and birth 
outside the United States together were highly predictive 
for TB (PPV 0.98, 95% CI 0.88–1.0). COPD was poorly 
predictive of TB (PPV 0.06, 95% CI 0.01–0.21). Age >50, 
US-born status, and COPD together had a PPV for TB of 
0.08, 95% CI 0.00–0.38 (Table 2; Figure).
Conclusions
In this population-based study comparing the 
demographic and clinical features of TB and NTM patients 
in a region of low TB incidence, we found that birthplace 
outside the United States, age, and the presence of COPD 
can accurately categorize 98% of patients in whom NTM 
disease is suspected. This information could be useful in 
making early isolation and treatment decisions in regions 
of low TB incidence.
According to recent surveillance data from the Centers 
for Disease Control and Prevention, 26 states had TB 
incidence similar to Oregon at <3 patients per 100,000 
population; nationwide, 59% of patients were born outside 
the United States (10). With regard to the proportion of 
patients who were not born in the United States, and the 
proportion of the general population who were not born in 
the United States, Oregon is similar to many other states 
with a low-incidence of TB. Fourteen states with low TB 
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Table 1. Demographic, clinical, and radiographic features of TB patients compared with NTM patients, Oregon, USA, 2005–2006* 
Characteristic 
No. (%) TB patients, 
n = 80† 
No. (%) NTM patients, 
n = 127 
Relative proportion 
(95% CI)  p value 
Demographics        
  Median age, y (range)  44 (5–86)  67 (12–92)  0.95 (0.93–0.96)  <0.01‡ 
  Male  49 (61)  48 (38)  1.6 (1.2–2.2)  <0.01 
  Not US born§  65 (81)  15 (19)  4.0 (2.5–6.3)  <0.01‡ 
Clinical signs and symptoms         
  Cough  58 (73)  98 (77)  0.9 (0.8–1.1)  0.45 
  Hemoptysis  12 (15)  28 (22)  0.7 (0.4–1.3)  0.21 
  Constitutional symptoms¶  56 (70)  61 (48)  1.5 (1.2–1.8)  0.03‡ 
Chest radiograph         
  Bronchiectasis  2 (3)  6 (5)  0.5 (0.1–2.6)  0.71 
  Cavity  18 (23)  11 (9)  2.7 (1.3–5.3)  <0.01 
  Effusion  10 (13)  8 (6)  2.1 (0.9–5.0)  0.10 
  Infiltrate  68 (87)  69 (54)  1.6 (1.3–1.9)  <0.01‡ 
  Lymphadenopathy  4 (5)  3 (2)  2.2 (0.5–9.4)  0.43 
Concurrent conditions         
  Immunosuppressive medications#  8 (10)  34 (27)  0.4 (0.2–0.8)  <0.01 
  COPD  2 (3)  29 (23)  0.1 (0.0–0.4)  0.19‡ 
  Previous TB  3 (4)  13 (10)  0.4 (0.1–1.2)  0.11 
  Diabetes  10 (13)  8 (6)  2.0 (0.8–4.8)  0.12 
  Tobacco smoking (previous or current)  26 (33)  53 (42)  0.8 (0.5–1.1)  0.19 
  Lung cancer  4 (5)  8 (6)  0.8 (0.2–2.6)  0.77 
 HIV/AIDS  0  4  (3)    0.30 
*TB, tuberculosis; NTM, nontuberculous mycobacteria; CI, confidence interval; COPD, chronic obstructive pulmonary disease. 
†Two TB patients excluded because of missing clinical data, 4 from multivariate analysis (n = 78). 
‡p value from multivariate analysis including COPD, age, not US born, constitutional symptoms, and infiltrate on radiograph. 
§54 (26%) patients excluded because of missing country of origin. 
¶Fever, night sweats, weight loss, or appetite loss. 
#Systemic corticosteroids, inhaled corticosteroids, disease-modifying anti-rheumatic drugs, tissue necrosis factor-Į inhibitors, cancer chemotherapy, and 
calcineurin inhibitors. incidence have >50% of TB cases occurring in non–US-
born patients in a setting in which <12.3% of the total 
population is not born in the United States. Furthermore, 
35 states had a similar racial composition to Oregon with 
a white, non-Hispanic population >72.6% (7). Oregon is 
therefore representative of many low-incidence TB areas 
within the United States.
Although the strength of this study is the population-
based data, this circumstance also leads to limitations. The 
ratio of TB to NTM prevalence in a given geographic area 
likely varies, which affects the degree to which our results 
can be generalized. Unfortunately, NTM disease prevalence 
rates are largely unknown. Marras et al. reported a similar 
prevalence of NTM isolation in Ontario, Canada, but a 
higher incidence of TB (11). They also reported ﬁ  nding 
fewer M. avium complex and more M. xenopi and rapidly-
growing mycobacteria (11). Regions less dominated by 
M. avium complex or with differing TB/NTM prevalence 
ratios might ﬁ   nd different associations. Additionally, 
further analysis of patients with smear-positive results was 
precluded by inadequate sample size. A subgroup analysis 
of smear positive patients in a larger cohort would be useful.
In summary, we found that TB and NTM could be 
reliably differentiated by determining patient’s birthplace, 
age, and presence of COPD. Until improved tools are 
developed for rapid mycobacterial diagnosis, these data 
might enable public health practitioners and clinicians in 
other regions with low TB incidence to plan more effective 
TB control efforts. 
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Table 2. PPVs of patient characteristics for tuberculosis in Oregon, USA, an area of low tuberculosis incidence, 2005–2006* 
Variable No. patients  No. TB cases  PPV for TB (95% CI) 
Age <50 y, not US born 44 43 0.98 (0.88–1.00) 
Age >50 y, US born, COPD 12 1 0.08 (0.00–0.38) 
COPD 31 2 0.06 (0.01–0.21) 
Age <50 y 70 49 0.70 (0.58–0.80) 
Not US born 80 65 0.81 (0.71–0.89) 
Infiltrate 137 68 0.50 (0.41–0.58) 
Constitutional symptoms 117 56 0.48 (0.39–0.57) 
*PPV using all patients (n = 207); tuberculosis cases = 80. PPV, positive predictive value; TB, tuberculosis; CI, confidence interval; COPD, chronic 
obstructive pulmonary disease.  
Figure. Positive predictive values (PPV) for tuberculosis of 
demographic and clinical factors in combination. TB, tuberculosis; 
COPD, chronic obstructive pulmonary disease; *9 patients missing 
birthplace; †45 patients missing birthplace.Distinguishing TB from NTM Disease, Oregon
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